Dynamic Auditory Cueing for Spatial Neglect in Stroke (NCT07507383) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Dynamic Auditory Cueing for Spatial Neglect in Stroke
Turkey (Türkiye)18 participantsStarted 2024-08-21
Plain-language summary
Spatial neglect is a common condition after stroke and can make it difficult for people to pay attention to one side of space. This problem can negatively affect daily activities and functional independence. This study aims to evaluate whether dynamic auditory cueing for spatial neglect (DAC-SN) can improve spatial neglect in people with stroke. Participants are randomly assigned to one of two groups. One group receives conventional rehabilitation, while the other group receives conventional rehabilitation combined with dynamic auditory cueing. Dynamic auditory cueing uses moving sounds to guide attention toward the affected side. The intervention is applied for about ten minutes per day, five days a week, for four weeks. Spatial neglect and functional outcomes are assessed using standardized clinical tests and scales at baseline and at predefined time points during and after the intervention. The results of this study may provide evidence for the use of auditory-based approaches in the rehabilitation of spatial neglect after stroke.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 years or older
* Subacute or chronic stroke
* Clinical diagnosis of left-sided spatial neglect confirmed by standardized tests (e.g., Line Bisection Test (LBT), Star Cancellation Test (SCT))
* Normal or corrected visual acuity
* Absence of auditory extinction
* Ability to understand and comply with study procedures
* Provision of written informed consent
Exclusion Criteria:
* Hearing impairment (Hearing Handicap Inventory score ≥26)
* Presence of hemianopia
* Impaired visual acuity due to ocular pathology (e.g., cataract, glaucoma)
* History of neurological disease (e.g., dementia, Parkinson's disease)
* Structural brain lesions unrelated to stroke
* Inability to participate in rehabilitation sessions or assessments
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Line Bisection Test (LBT) deviation score
Timeframe: Baseline, after 1 session, after 10 sessions, and after 20 sessions (end of treatment)
2
Catherine Bergego Scale (CBS) score
Timeframe: Baseline and after 20 sessions (end of treatment)